Elite Pharmaceuticals Files 8-K
Ticker: ELTP · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1053369
| Field | Detail |
|---|---|
| Company | Elite Pharmaceuticals INC /NV/ (ELTP) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Regulation FD
Related Tickers: ELTP
TL;DR
Elite Pharma filed a routine 8-K, no major news.
AI Summary
Elite Pharmaceuticals, Inc. filed an 8-K on October 7, 2024, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Elite Pharmaceuticals is meeting its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not disclose any new material risks or significant negative events.
Key Players & Entities
- ELITE PHARMACEUTICALS, INC. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- New Jersey (jurisdiction) — State of principal executive offices
FAQ
What is the purpose of this 8-K filing?
This 8-K filing serves as a Current Report for Elite Pharmaceuticals, Inc., primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was this report filed?
The report was filed on October 7, 2024.
What is the principal executive office address for Elite Pharmaceuticals?
The principal executive offices are located at 165 Ludlow Avenue, Northvale, New Jersey 07647.
What is the IRS Employer Identification Number for Elite Pharmaceuticals?
The IRS Employer Identification Number is 22-3542636.
Does this filing indicate any new financial results or material events?
Based on the provided text, this filing appears to be a standard report and does not explicitly detail new financial results or material events beyond the reporting categories.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-10-07 16:20:25
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ELTP OTCQB Item 7.01 Re
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001493152-24-040288.txt ( ) — 229KB
- eltp-20241007.xsd (EX-101.SCH) — 3KB
- eltp-20241007_lab.xml (EX-101.LAB) — 33KB
- eltp-20241007_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 October 7, 2024 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC . (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 165 Ludlow Avenue , Northvale , New Jersey 07647 (Address of principal executive offices) (201) 750-2646 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ELTP OTCQB Item 7.01 Regulation FD Disclosure. On October 7, 2024, Elite Pharmaceuticals, Inc. ("Elite" or the "Company") issued a press release to announce the launch of Elite's generic version of Tylenol with Codeine (acetaminophen and codeine phosphate) 300mg/15mg, 300mg/30mg, and 300mg/60mg tablets. This product is marketed and sold under the Elite Laboratories, Inc. label. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of Elite's filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated October 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 7, 2024 ELITE PHARMACEUTICALS, INC. By: /s/ Nasrat Hakim Nasrat Hakim, President and CEO